Cyclothiazide potentiates agonist responses at human AMPA/kainate receptors expressed in oocytes.
暂无分享,去创建一个
P. May | J P Burnett | N G Mayne | N. Mayne | J. Burnett | Y M Snyder | R L Sharp | P C May | Y. M. Snyder | R. L. Sharp
[1] Á. Pataki,et al. Electrophysiological studies with a 2,3-benzodiazepine muscle relaxant: GYKI 52466. , 1989, European journal of pharmacology.
[2] B. O'dowd,et al. A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors , 1992, Nature.
[3] S. Ozawa,et al. Agonist- and subunit-dependent potentiation of glutamate receptors by a nootropic drug aniracetam. , 1992, Brain research. Molecular brain research.
[4] P. May,et al. Cyclothiazide Treatment Unmasks AMPA Excitotoxicity in Rat Primary Hippocampal Cultures , 1993, Journal of neurochemistry.
[5] J. Olney,et al. A benzodiazepine recognition site associated with the non-NMDA glutamate receptor , 1993, Neuron.
[6] L. Vyklický,et al. Hippocampal neurons exhibit cyclothiazide-sensitive rapidly desensitizing responses to kainate , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[7] D. Lodge,et al. Cyclothiazide reverses AMPA receptor antagonism of the 2,3-benzodiazepine, GYKI 53655. , 1993, European journal of pharmacology.
[8] M. Rogawski,et al. GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses , 1993, Neuron.